HICKSVILLE, NY, Sept. 20, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Canbiola, Inc. (OTC PINK: CANB) in its continuing effort to attract and partner with industry experts in
the Global Health and Wellness field is proud to announced today that Dr. David J. Weissberg is joining the Medical Advisory Board
and has also signed on as a Private Label customer.
Dr. Weissberg stated, “I’m very pleased to join the Medical Advisory team, to both collaborate on new products and explore the
benefits of CBD for patients. To date, I have used this product on both myself and dozens of my patients and have been very
satisfied with both the potent non-narcotic pain relief it affords my patients as well as the low risk of adverse side effects
commonly seen in both traditional non-steroidal anti-inflammatory drugs and narcotic medications. CBD has very potent
anti-inflammatory properties bringing down the swelling, stiffness, and warmth seen in arthritic joints and post-traumatic
injuries. I believe that many physician specialties will find good indications for its use making it a very affordable and safe
medication without the high risks associated with traditional prescription drugs. Additionally, Chiropractors who are unable to
prescribe medications will be able to offer this over the counter medication for their patients who frequently suffer from both
post-traumatic and neurologic injuries. The research and results thus far are very compelling and I’m excited for the prospects
these products will offer for a variety of ailments. I will strive to help the Canbiola team put the best products possible on the
market for both consumers and patients”.
Marco Alfonsi, Canbiola CEO, stated, “We are continuing to execute our plan to strengthen not only our Medical Advisory Board
but also our distribution network. With the addition of Dr. Weissberg, we have added the 8th doctor to our Medical Advisory Board.
I believe this addition will benefit our product development, to have true medical experts advise and offer input as we develop new
products is an invaluable resource. Coupling the continued and increased acceptance of CBD with our development of new products for
different uses will continue our growth and sales while expanding our client base. At Canbiola we are building an extraordinary
team, and look to be an industry leader going forward. My enthusiasm for our future and the direction of the industry as a whole is
very strong, I want to thank our team and shareholders for their support.”
Dr. Weissberg joins a growing all-star medical advisory team that already has the following members:
Dr. Maciej Matt Ferenc joins Canbiola as Medical Advisor and Distributor
Dr. Channing Coe joins Canbiola as Medical Advisor and Distributor
Dr. Robert A. Kornfeld Joins Canbiola, Inc. (CANB) as Medical Advisor and Distributor
Dr. John P. Salerno Joins Canbiola, Inc. (CANB) as Medical Advisor and Distributor
Dr. Patrick M. Fratellone Joins Canbiola, Inc. (CANB) as Medical Advisor and Distributor
Dr. Harry Benisatto joins Canbiola, Inc. (CANB) as Medical Advisor and Distributor
Dr. Smita Ohri joins Canbiola as Medical Advisor and Distributor
About Dr. Weissberg:
Over 25 years in private practice, Dr. Weissberg has honed a meticulous and moderate approach to orthopedic care. A co-owner of
the Melville Surgery Center and certified in the ImPACT™ Protocol – served as team physician for the Huntington, Walt Whitman, and
Northport high school football teams, he is expert in the diagnosis and treatment of musculoskeletal injuries and conditions. He
specializes in the arthroscopic treatment of shoulder, knee and ankle problems, including meniscal injuries, anterior cruciate
ligament tears, labral and rotator tears, impingement syndromes, and instability issues.
Long Island Orthopedic Solutions (6 locations and 30,000+ patients)
Comprehensive, Conservative Treatment and Rehabilitation Options
That’s Long Island Orthopedic Solutions: minimal invasion with maximum results. The most advanced technological treatments and
physical therapy combine to encourage the body’s natural healing abilities, providing quicker results while often avoiding
traditional surgical options.
With over five decades of combined experience, our clinical staff is expert in time-tested medicines and therapies and the
latest diagnosis and treatment protocols, including surgical and nonsurgical orthopedic solutions and ImPACT™ (Immediate
Post-Concussion Assessment and Cognitive Testing) computerized evaluation tools and services.
About Canbiola, Inc.
Canbiola, Inc. is a public company trading under symbol CANB.
Canbiola, Inc. is a US Company embarking in the sale of a variety of Cannabidiol (CBD) based products. Canbiola is in the
process of developing its own line of proprietary products as well as seeking synergistic value through acquisitions in the CBD and
the medical cannabis industry. Cannabis is currently federally illegal and has legalized for medical purposes in some form in a
limited number of states. The company has already launched several products found at www.canbiola.com.
The company also owns two technological solutions, WRAPmail (US Patent 8,572,275), which turns traditional email into a powerful
marketing and branding tool, as well Prosperity Systems and the Bullseye platform of document management and compliance targeted at
broker-dealers, public companies, and governmental agencies providing a flawless all-in-one solution for document management,
retention and compliance.
Forward-looking statements and risks and uncertainties Matters discussed in this press release contain forward-looking
statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such
forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated,
expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of
risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of
economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein
should not be construed in any way, shape or manner of our future financial condition or stock price.
Follow us on Twitter and Facebook
CONTACT INFORMATION Canbiola Investor Relations Email: IR@canbiola.com Phone: (516) 595-9544 Website: http://www.canbiola.com Follow us on Twitter and Facebook
